Mary V. Relling

Q: What Schools Are Affiliated With Mary V. Relling

Mary V. Relling is affiliated with the following schools: University of Alberta, University of Arizona, University of California, Los Angeles, University of Bari, University of Chicago, University of California, San Francisco, University of Tennessee Health Science Center, Massachusetts General Hospital, University of Alabama at Birmingham

Mary V. Relling's AcademicInfluence.com Rankings

Mary V. Relling

Medical

#1734

World Rank

#2105

Historical Rank

Pharmacology

#169

World Rank

#208

Historical Rank

medical Degrees

Download Badge

Medical

Why Is Mary V. Relling Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Mary Violet Relling is an American pharmacogeneticist. Relling's research focuses on pharmacokinetics and pharmacodynamics in children and how genome variability influences a child's response to cancer chemotherapy.

(See a Problem?)

Mary V. Relling's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression (2001) (2153)
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. (2002) (1998)
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia (2007) (1753)
Treating childhood acute lymphoblastic leukemia without cranial irradiation. (2009) (1051)
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. (2009) (1048)
BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros (2008) (1031)
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. (2014) (1029)
Molecular Diagnosis of Thiopurine S-Methyltransferase Deficiency: Genetic Basis for Azathioprine and Mercaptopurine Intolerance (1997) (755)
Moving towards individualized medicine with pharmacogenomics (2004) (748)
Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. (1999) (696)
Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. (2015) (644)
Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. (2004) (601)
Pharmacogenomics in the clinic (2015) (583)
THE GENOMIC LANDSCAPE OF PEDIATRIC AND YOUNG ADULT T-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA (2017) (569)
Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? (2012) (498)
Germline genomic variants associated with childhood acute lymphoblastic leukemia (2009) (473)
Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. (2004) (467)
Implementing genomic medicine in the clinic: the future is here (2013) (463)
Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. (2003) (421)
Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. (2010) (390)
High incidence of secondary brain tumours after radiotherapy and antimetabolites (1999) (387)
Nomenclature for N-acetyltransferases. (1995) (378)
Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia. (2004) (372)
Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. (1999) (369)
Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. (2015) (357)
Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC) (2016) (353)
NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity (2016) (350)
Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process (2014) (346)
Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. (2015) (332)
Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update (2019) (331)
Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma. (2001) (326)
Acute lymphoblastic leukemia. (2004) (321)
Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. (2009) (321)
The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. (2001) (299)
Racial and gender differences in N‐acetyltransferase, xanthine oxidase, and CYP1A2 * activities (1992) (298)
Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. (2011) (286)
Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia (2015) (276)
P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. (1996) (274)
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia (2019) (274)
Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. (2007) (273)
Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. (2013) (259)
Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse (2013) (257)
Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group (2019) (256)
Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children's oncology group. (2012) (255)
Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia (2011) (244)
Pediatric acute lymphoblastic leukemia. (2003) (244)
Pharmacogenetics and cancer therapy (2001) (242)
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. (2009) (242)
The Pharmacogenetics Research Network: From SNP Discovery to Clinical Drug Response (2007) (242)
Multiplex Assessment of Protein Variant Abundance by Massively Parallel Sequencing (2018) (238)
Immediate Hypersensitivity to Polyethylene Glycols and Polysorbates: More Common Than We Have Recognized. (2019) (238)
Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. (2012) (234)
Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. (2010) (231)
Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. (2014) (230)
Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group. (2012) (225)
Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. (1990) (222)
Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. (1995) (220)
Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. (2014) (220)
Simultaneous characterization of glutathione S-transferase M1 and T1 polymorphisms by polymerase chain reaction in American whites and blacks. (1996) (216)
Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations. (2013) (212)
Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. (2015) (211)
PG4KDS: A model for the clinical implementation of pre‐emptive pharmacogenetics (2014) (211)
Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. (2004) (209)
Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. (1998) (207)
Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline‐related congestive heart failure after childhood cancer (2008) (206)
Patient characteristics associated with high-risk methotrexate concentrations and toxicity. (1994) (203)
Deregulation of DUX4 and ERG in acute lymphoblastic leukemia (2016) (197)
Variability in human cytochrome P450 paclitaxel metabolism. (1995) (193)
Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. (1996) (193)
Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. (2003) (192)
Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. (2008) (192)
Ancestry and pharmacogenetics of antileukemic drug toxicity. (2007) (188)
Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. (1994) (187)
Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. (2000) (186)
Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. (2009) (184)
Global implementation of genomic medicine: We are not alone (2015) (183)
A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. (2013) (182)
Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies. (2011) (179)
Development and use of active clinical decision support for preemptive pharmacogenomics (2013) (177)
Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia (1998) (176)
Results of therapy for acute lymphoblastic leukemia in black and white children. (2003) (176)
TOPOISOMERASE II INHIBITOR‐RELATED ACUTE MYELOID LEUKAEMIA (2000) (171)
Higher Frequency of Glutathione S-Transferase Deletions in Black Children With Acute Lymphoblastic Leukemia (1997) (170)
Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. (2005) (170)
Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia (2000) (168)
Genome-wide study of methotrexate clearance replicates SLCO1B1. (2013) (167)
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Overcoming Challenges of Real‐World Implementation (2013) (166)
ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia. (2012) (165)
O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. (1994) (164)
Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies (1997) (163)
Pharmacogenomics: Challenges and Opportunities (2006) (162)
Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. (2015) (159)
Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. (2000) (157)
Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia. (2004) (157)
6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group study. (2014) (151)
Genome-wide association studies in pharmacogenomics: successes and lessons (2013) (150)
Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. (1997) (148)
Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. (1994) (144)
Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. (2005) (143)
Proximal Tubular Secretion of Creatinine by Organic Cation Transporter OCT2 in Cancer Patients (2012) (142)
Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells. (2001) (142)
Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. (2008) (141)
Clinical Pharmacokinetics of Paclitaxel (1994) (141)
Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. (2003) (140)
Transporter-mediated protection against thiopurine-induced hematopoietic toxicity. (2008) (139)
Germline Genetic Variation in ETV6 and Risk of Childhood Acute Lymphoblastic Leukemia: a Systematic Genetic Study (2015) (139)
Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells (2003) (138)
Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells (2003) (138)
Sex differences in prognosis for children with acute lymphoblastic leukemia. (1999) (137)
The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later (2020) (134)
Development and implementation of a pharmacist-managed clinical pharmacogenetics service. (2011) (133)
Improved prognosis for older adolescents with acute lymphoblastic leukemia. (2010) (127)
Pharmacogenomics (2019) (125)
Epipodophyllotoxin-related acute myeloid leukemia: a study of 35 cases. (1995) (125)
Clinical Impact of Minimal Residual Disease in Children with Different Subtypes of Acute Lymphoblastic Leukemia Treated with Response-Adapted Therapy (2016) (124)
Inherited genetic variation in childhood acute lymphoblastic leukemia. (2015) (124)
Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. (2004) (122)
Thiopurine methyltransferase in acute lymphoblastic leukemia. (2006) (122)
Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia. (2018) (121)
Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr1 genes. (2000) (121)
Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients (2003) (119)
Clinical Pharmacokinetics-Pharmacodynamics of Anticancer Drugs (1989) (119)
PharmGKB summary: methotrexate pathway. (2011) (117)
Framework for development of physician competencies in genomic medicine: report of the Competencies Working Group of the Inter-Society Coordinating Committee for Physician Education in Genomics (2014) (117)
Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16. (2019) (116)
NALP3 inflammasome up-regulation and CASP1 cleavage of the glucocorticoid receptor causes glucocorticoid resistance in leukemia cells (2015) (116)
Topotecan Combination Chemotherapy in Two New Rodent Models of Retinoblastoma (2005) (114)
Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulation. (1999) (113)
Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy: a report from the children's oncology group. (2014) (113)
Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells (2011) (112)
Systemic Exposure to Thiopurines and Risk of Relapse in Children With Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. (2015) (107)
TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children. (2018) (106)
Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. (2012) (106)
Childhood acute lymphoblastic leukemia. (2007) (106)
Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia. (2015) (104)
A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group. (2008) (104)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Rasburicase Therapy in the Context of G6PD Deficiency Genotype (2014) (103)
Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: A Children's Oncology Group Study [corrected]. (2008) (103)
Nomenclature for alleles of the thiopurine methyltransferase gene (2013) (102)
Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies. (2002) (99)
Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity. (1997) (99)
Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. (2010) (98)
Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin‐oxidation and N‐acetylation phenotypes in children (1989) (96)
A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. (2014) (95)
Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects (1991) (94)
Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects (2018) (93)
Higher frequency of glutathione S-transferase deletions in black children with acute lymphoblastic leukemia. (1997) (92)
Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia. (2006) (92)
A mouse model for glucocorticoid‐induced osteonecrosis: Effect of a steroid holiday (2009) (91)
Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. (2012) (90)
HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies. (2014) (90)
Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia (2005) (89)
Reappraisal of the clinical and biologic significance of myeloid-associated antigen expression in childhood acute lymphoblastic leukemia. (1998) (88)
Phase I trial of paclitaxel in children with refractory solid tumors: a Pediatric Oncology Group Study. (1993) (87)
De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo. (2002) (86)
In Vivo Response to Methotrexate Forecasts Outcome of Acute Lymphoblastic Leukemia and Has a Distinct Gene Expression Profile (2008) (85)
Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia. (2016) (83)
Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia. (2005) (79)
Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia. (1994) (79)
Human cytochrome P450 metabolism of teniposide and etoposide. (1992) (79)
Novel variants in NUDT15 and thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry. (2017) (78)
Genetic Variations in GRIA1 on Chromosome 5q33 Related to Asparaginase Hypersensitivity (2010) (78)
Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypes (2005) (78)
Individualized dosages of chemotherapy as a strategy to improve response for acute lymphocytic leukemia. (1991) (78)
A substrate specific functional polymorphism of human gamma-glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells. (2004) (77)
Thiopurine pathway. (2010) (74)
Isolation of a human thiopurine S‐methyltransferase (TPMT) complementary DNA with a single nucleotide transition A719G (TPMT*3C) and its association with loss of TPMT protein and catalytic activity in humans (1998) (74)
Outcome of children with hypodiploid ALL treated with risk-directed therapy based on MRD levels. (2015) (74)
CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. (2004) (72)
Removal of methotrexate, leucovorin, and their metabolites by combined hemodialysis and hemoperfusion (1988) (69)
Inherited coding variants at the CDKN2A locus influence susceptibility to acute lymphoblastic leukaemia in children (2015) (67)
Mutational landscape and patterns of clonal evolution in relapsed pediatric acute lymphoblastic leukemia. (2020) (67)
Genome-wide analysis links NFATC2 with asparaginase hypersensitivity. (2015) (67)
Evidence and resources to implement pharmacogenetic knowledge for precision medicine. (2016) (65)
Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease (2016) (65)
Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia. (2011) (65)
Neuropathic pain during treatment for childhood acute lymphoblastic leukemia (2011) (65)
Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs? (1996) (63)
Etoposide achieves potentially cytotoxic concentrations in CSF of children with acute lymphoblastic leukemia. (1996) (62)
Molecular emergence of acute myeloid leukemia during treatment for acute lymphoblastic leukemia (2001) (62)
Genetic Studies of a Cluster of Acute Lymphoblastic Leukemia Cases in Churchill County, Nevada (2006) (62)
Massively parallel variant characterization identifies NUDT15 alleles associated with thiopurine toxicity (2020) (61)
The SWI/SNF chromatin-remodeling complex and glucocorticoid resistance in acute lymphoblastic leukemia. (2008) (60)
Severe hypertriglyceridaemia during therapy for childhood acute lymphoblastic leukaemia. (2014) (58)
CYP1A2 and CYP2D6 4-hydroxylate propranolol and both reactions exhibit racial differences. (2000) (57)
Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia. (2009) (57)
The changing burden of long-term health outcomes in survivors of childhood acute lymphoblastic leukaemia: a retrospective analysis of the St Jude Lifetime Cohort Study. (2019) (57)
PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity. (2012) (56)
Methotrexate intracellular disposition in acute lymphoblastic leukemia: a mathematical model of gamma-glutamyl hydrolase activity. (2002) (55)
Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes. (2014) (55)
Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia. (2015) (53)
Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment. (2005) (53)
Polymorphic drug metabolism. (1989) (53)
Age‐related differences in hepatic drug clearance in children: Studies with lorazepam and antipyrine (1991) (52)
Assay of 6-mercaptopurine and its metabolites in patient plasma by high-performance liquid chromatography with diode-array detection. (1999) (51)
Antibodies Predict Pegaspargase Allergic Reactions and Failure of Rechallenge. (2019) (50)
Utility of early screening magnetic resonance imaging for extensive hip osteonecrosis in pediatric patients treated with glucocorticoids. (2015) (50)
Opportunities, resources, and techniques for implementing genomics in clinical care (2019) (49)
Persistence of lymphoblasts in bone marrow on day 15 and days 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia. (2002) (48)
HPLC determination of thiopurine nucleosides and nucleotides in vivo in lymphoblasts following mercaptopurine therapy. (2002) (48)
Asparaginase Potentiates Glucocorticoid-Induced Osteonecrosis in a Mouse Model (2016) (48)
Resumption of high‐dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients (2012) (48)
Anticancer drugs as inhibitors of two polymorphic cytochrome P450 enzymes, debrisoquin and mephenytoin hydroxylase, in human liver microsomes. (1989) (47)
Cancer Pharmacogenomics and Pharmacoepidemiology: Setting a Research Agenda to Accelerate Translation (2010) (47)
Role of pharmacogenomics and pharmacodynamics in the treatment of acute lymphoblastic leukaemia. (2002) (47)
Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia (2021) (47)
Etoposide pharmacokinetics and pharmacodynamics after acute and chronic exposure to cisplatin (1994) (46)
CRHR1 polymorphisms predict bone density in survivors of acute lymphoblastic leukemia. (2008) (46)
Modeling Mechanisms of In Vivo Variability in Methotrexate Accumulation and Folate Pathway Inhibition in Acute Lymphoblastic Leukemia Cells (2010) (46)
Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial. (2011) (45)
Relationship between cytotoxicity and site-specific DNA recombination after in vitro exposure of leukemia cells to etoposide. (1996) (44)
Etoposide induces chimeric Mll gene fusions (2004) (44)
A PAI-1 ( SERPINE 1 ) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia : a report from the Children ’ s Oncology Group (2008) (44)
Acute lymphoblastic leukemia with TEL-AML1 fusion has lower expression of genes involved in purine metabolism and lower de novo purine synthesis. (2004) (44)
Thioguanine substitution alters DNA cleavage mediated by topoisomerase II (2000) (44)
Etoposide causes illegitimate V(D)J recombination in human lymphoid leukemic cells. (1996) (44)
Clinical and biological characteristics of acute lymphocytic leukemia in children with Down syndrome. (2005) (43)
Primary epiphyseal arteriopathy in a mouse model of steroid-induced osteonecrosis. (2013) (43)
Genetic predictors of glucocorticoid-induced hypertension in children with acute lymphoblastic leukemia (2008) (43)
Identification of four novel associations for B-cell acute lymphoblastic leukaemia risk (2019) (43)
Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia (1994) (42)
Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group. (2008) (41)
A Comparison of the Pharmacokinetics and Pharmacodynamics of Docetaxel between African-American and Caucasian Cancer Patients: CALGB 9871 (2007) (41)
Differential effects of targeted disruption of thiopurine methyltransferase on mercaptopurine and thioguanine pharmacodynamics. (2007) (41)
Overt testicular disease at diagnosis of childhood acute lymphoblastic leukemia: lack of therapeutic role of local irradiation (2005) (40)
Novel susceptibility variants at the ERG locus for childhood acute lymphoblastic leukemia in Hispanics. (2019) (40)
Should Pharmacogenomic Studies be Required for New Drug Approval? (2007) (40)
Cerebrospinal fluid asparagine concentrations after Escherichia coli asparaginase in children with acute lymphoblastic leukemia. (1999) (39)
Pharmacokinetics of Anticancer Drugs in Children (1987) (39)
Expression of SMARCB1 modulates steroid sensitivity in human lymphoblastoid cells: identification of a promoter SNP that alters PARP1 binding and SMARCB1 expression. (2007) (38)
Creation of Polarized Cells Coexpressing CYP3A4, NADPH Cytochrome P450 Reductase and MDR1/P-glycoprotein (2004) (38)
Simultaneous administration of multiple model substrates to assess hepatic drug clearance (1987) (38)
Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments (2013) (37)
Pharmacogenetics of Human Carbonyl Reductase 1 (CBR1) in Livers from Black and White Donors (2009) (36)
Etoposide pathway. (2009) (36)
A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia (2002) (36)
Phase I targeted systemic exposure study of paclitaxel in children with refractory acute leukemias. (1999) (35)
Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy. (2021) (35)
Genome-wide approach to identify risk factors for therapy-related myeloid leukemia (2006) (34)
Asparaginase formulation impacts hypertriglyceridemia during therapy for acute lymphoblastic leukemia (2020) (33)
Phase I study of oral etoposide in children with refractory solid tumors. (1994) (33)
Chemotherapy Induced Nausea and Emesis in Pediatric Cancer Patients: External Validity of Child and Parent Emesis Ratings (1993) (33)
Late-onset delayed excretion of methotrexate (2004) (33)
Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia (2020) (33)
Pharmacokinetics and pharmacodynamics of 21‐day continuous oral etoposide in pediatric patients with solid tumors (1995) (32)
Epigenetic regulation of human gamma-glutamyl hydrolase activity in acute lymphoblastic leukemia cells. (2006) (32)
Evidence for Age As a Modifier of Genetic Associations for Lipid Levels (2011) (32)
Simultaneous quantitation of etoposide and its catechol metabolite in human plasma using high-performance liquid chromatography with electrochemical detection. (1999) (31)
Inherited genetic susceptibility of acute lymphoblastic leukemia in Down syndrome. (2019) (31)
Genome-wide association study of susceptibility loci for T-cell acute lymphoblastic leukemia in children. (2019) (31)
PharmGKB Update: II. CYP3A5, Cytochrome P450, Family 3, Subfamily A, Polypeptide 5 (2004) (31)
Pharmacokinetics of paclitaxel in an anephric patient (1999) (31)
The genomic landscape of pediatric acute lymphoblastic leukemia (2022) (31)
Lymphoid gene expression as a predictor of risk of secondary brain tumors (2005) (30)
Prognostic impact of absolute lymphocyte counts at the end of remission induction in childhood acute lymphoblastic leukemia (2013) (30)
Changes in body mass index, height, and weight in children during and after therapy for acute lymphoblastic leukemia (2018) (30)
Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia. (2003) (30)
Enhancer hijacking drives oncogenic BCL11B expression in lineage ambiguous stem cell leukemia. (2021) (29)
Global Pharmacogenomics Within Precision Medicine: Challenges and Opportunities (2019) (29)
A modified forward multiple regression in high‐density genome‐wide association studies for complex traits (2009) (28)
FUNCTIONAL CHARACTERIZATION OF ABCC2 PROMOTER POLYMORPHISMS AND ALLELE SPECIFIC EXPRESSION (2012) (28)
ELISA to evaluate plasma anti-asparaginase IgG concentrations in patients with acute lymphoblastic leukemia. (2000) (28)
High-throughput asparaginase activity assay in serum of children with leukemia. (2013) (27)
Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932 (2021) (27)
Comparison of self-report and electronic monitoring of 6MP intake in childhood ALL: a Children's Oncology Group study. (2017) (27)
Gazing into a crystal ball–cancer therapy in the post-genomic era (2001) (26)
Differences in teniposide disposition and pharmacodynamics in patients with newly diagnosed and relapsed acute lymphocytic leukemia. (1992) (26)
Neurocognitive Functioning of Children Treated for High-Risk B-Acute Lymphoblastic Leukemia Randomly Assigned to Different Methotrexate and Corticosteroid Treatment Strategies: A Report From the Children's Oncology Group. (2017) (26)
Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients (2015) (25)
Next Generation Transcriptomic Resequencing Identifies Novel Genetic Alterations in High-Risk (HR) Childhood Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG) HR ALL TARGET Project. (2009) (24)
Pharmacokinetics of daunorubicin and daunorubicinol in infants with leukemia treated in the interfant 99 protocol (2010) (24)
Limited and Optimal Sampling Strategies for Etoposide and Etoposide Catechol in Children with Leukemia (2002) (24)
Pharmacogenetic analysis of interindividual irinotecan (CPT-11) pharmacokinetic (PK) variability: Evidence for a functional variant of ABCC2 (2004) (24)
Genome scan implicates adhesion biological pathways in secondary leukemia (2007) (24)
Preemptive Clinical Pharmacogenetics Implementation: Current programs in five United States medical centers (2015) (23)
Treatment of Childhood Acute Lymphoblastic Leukaemia (1988) (23)
Bone mineral density in children with acute lymphoblastic leukemia (2018) (22)
Pharmacogenomics of acute lymphoid leukemia: new insights into treatment toxicity and efficacy. (2013) (20)
Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginase (2014) (20)
Mercaptopurine Ingestion Habits, Red Cell Thioguanine Nucleotide Levels, and Relapse Risk in Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group Study AALL03N1. (2017) (19)
A New System Identification Approach to Identify Genetic Variants in Sequencing Studies for a Binary Phenotype (2014) (19)
Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse (2008) (19)
Merging Electronic Health Record Data and Genomics for Cardiovascular Research: A Science Advisory From the American Heart Association (2016) (18)
Higher activity of polymorphic NAD(P)H:quinone oxidoreductase in liver cytosols from blacks compared to whites. (2006) (18)
Hypersensitivity reactions to asparaginase in mice are mediated by anti-asparaginase IgE and IgG and the immunoglobulin receptors FcεRI and FcγRIII (2018) (18)
Variability in Teniposide Plasma Protein Binding Is Correlated With Serum Albumin Concentrations (1992) (18)
Effect of Premedications in a Murine Model of Asparaginase Hypersensitivity (2015) (18)
Evidence synthesis and guideline development in genomic medicine: current status and future prospects (2014) (17)
Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up‐front treatment of acute lymphoblastic leukemia (2003) (17)
Substrain-specific differences in survival and osteonecrosis incidence in a mouse model. (2012) (17)
Population PK/PD Model of Homocysteine Concentrations after High-Dose Methotrexate Treatment in Patients with Acute Lymphoblastic Leukemia (2012) (17)
Predicting success of desensitization after pegaspargase allergy. (2019) (17)
Global gene expression as a function of germline genetic variation. (2005) (16)
Association of GSTM1 null variant with anthracycline-related cardiomyopathy after childhood cancer-A Children's Oncology Group ALTE03N1 report. (2020) (16)
Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia (2015) (15)
Effect of a Daily Text Messaging and Directly Supervised Therapy Intervention on Oral Mercaptopurine Adherence in Children With Acute Lymphoblastic Leukemia (2020) (15)
How to solve the problem of hypersensitivity to asparaginase? (2018) (15)
Alteration of RNA Splicing by Small-Molecule Inhibitors of the Interaction between NHP2L1 and U4 (2018) (14)
Increased CYP3A4 copy number in TONG/HCC cells but not in DNA from other humans (2006) (14)
A comprehensive evaluation of collapsing methods using simulated and real data: excellent annotation of functionality and large sample sizes required (2014) (14)
Polymorphisms in the MLL breakpoint cluster region (BCR) (2003) (14)
Clinical Implementation of Pharmacogenetics: More than One Gene at a Time (2013) (14)
Noncoding genetic variation in GATA3 increases acute lymphoblastic leukemia risk through local and global changes in chromatin conformation (2022) (13)
Stability of etoposide solution for oral use. (1992) (13)
The changing burden of long-term health outcomes in survivors of childhood acute lymphoblastic leukaemia: a retrospective analysis of the St Jude lifetime cohort study (2019) (13)
Genetics of pleiotropic effects of dexamethasone (2017) (13)
Is mega dose of methotrexate beneficial to patients with acute lymphoblastic leukemia? (2006) (13)
The frequency of illegitimate V(D)J recombinase-mediated mutations in children treated with etoposide-containing antileukemic therapy. (1998) (13)
Preemptively Precise: Returning and Updating Pharmacogenetic Test Results to Realize the Benefits of Preemptive Testing (2019) (13)
Phase I Study of Flavone Acetic Acid (NSC 347512, LM975) in Patients with Pediatric Malignant Solid Tumors (1991) (13)
Genome-Wide Association Analyses Identify Susceptibility Loci For Vincristine-Induced Peripheral Neuropathy In Children With Acute Lymphoblastic Leukemia (2013) (12)
Prophylactic Trimethoprim-Sulfamethoxazole Does Not Affect Pharmacokinetics or Pharmacodynamics of Methotrexate (2016) (12)
Individual-specific functional epigenomics reveals genetic determinants of adverse metabolic effects of glucocorticoids. (2021) (12)
Development of a postgraduate year 2 pharmacy residency in clinical pharmacogenetics. (2017) (11)
Concordance between glucose-6-phosphate dehydrogenase (G6PD) genotype and phenotype and rasburicase use in patients with hematologic malignancies (2018) (11)
Pharmacogenetic analysis of interindividual irinotecan (CPT-11) pharmacokinetic (PK) variability: Evidence for a functional variant of ABCC2. (2004) (11)
Association of GATA3 polymorphisms with minimal residual disease and relapse risk in childhood acute lymphoblastic leukemia. (2020) (11)
Effect of allopurinol versus urate oxidase on methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia (2009) (11)
Integrated Analysis of Pharmacokinetic, Clinical, and SNP Microarray Data Using Projection onto the Most Interesting Statistical Evidence with Adaptive Permutation Testing (2009) (10)
Polymorphisms in candidate genes in patients with congestive heart failure (CHF) after childhood cancer: A Report from the Childhood Cancer Survivor Study (CCSS). (2006) (10)
Host thiopurine methyltransferase status affects mercaptopurine antileukemic effectiveness in a murine model (2014) (10)
The thirteenth international childhood acute lymphoblastic leukemia workshop report: La Jolla, CA, USA, December 7–9, 2011 (2013) (10)
The effect of atovaquone on etoposide pharmacokinetics in children with acute lymphoblastic leukemia (2001) (10)
Automated high-performance liquid chromatographic assay for the determination of 7-ethoxycoumarin and umbelliferone. (1992) (10)
LYMPHOID NEOPLASIA Genome-wide analysis links NFATC 2 with asparaginase hypersensitivity (2015) (9)
Serum Alanine Aminotransferase Elevations in Survivors of Childhood Cancer: A Report From the St. Jude Lifetime Cohort Study (2018) (9)
Differential effects of thiopurine methyltransferase (TPMT) and multidrug resistance-associated protein gene 4 (MRP4) on mercaptopurine toxicity (2017) (9)
Genetic nondiscrimination legislation: a critical prerequisite for pharmacogenomics data sharing. (2007) (9)
Essential Characteristics of Pharmacogenomics Study Publications (2018) (9)
Optimizing thiopurine dosing based on TPMT and NUDT15 genotypes: It takes two to tango (2019) (9)
Palmar‐plantar erythrodysesthesia syndrome following treatment with high‐dose methotrexate or high‐dose cytarabine (2017) (9)
A human lymphoid leukemia cell line with a V(D)J recombinase-mediated deletion of hprt. (1998) (9)
Profiling chromatin accessibility in pediatric acute lymphoblastic leukemia identifies subtype-specific chromatin landscapes and gene regulatory networks (2021) (9)
Factors Associated with Declining to Participate in a Pediatric Oncology Next Generation Sequencing Study. (2020) (9)
SVSI: Fast and Powerful Set‐Valued System Identification Approach to Identifying Rare Variants in Sequencing Studies for Ordered Categorical Traits (2015) (9)
Anthracycline-related cardiomyopathy in childhood cancer survivors and association with polymorphisms in the carbonyl reductase genes: A Children's Oncology Group study. (2010) (9)
Bloodstream infections exacerbate incidence and severity of symptomatic glucocorticoid‐induced osteonecrosis (2019) (8)
CYP2D6, N‐Acetylation, and Xanthine Oxidase Activity in Cystic Fibrosis (1996) (8)
A permutation-based method to identify loss-of-heterozygosity using paired genotype microarray data (2008) (8)
Mutations in the RAS Signaling, B-Cell Development, TP53/RB1, and JAK Signaling Pathways Are Common in High Risk B-Precursor Childhood Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG) High-Risk (HR) ALL TARGET Project. (2009) (8)
Drug-induced hemorrhagic cystitis. (1986) (8)
Current Treatment and Results of St. Jude Studies for Childhood Acute Lymphoblastic Leukemia (1994) (8)
Hypertension is a modifiable risk-factor for osteonecrosis in acute lymphoblastic leukemia. (2019) (8)
Genomic Medicine Year in Review: 2019. (2019) (7)
Identification of small molecules that mitigate vincristine‐induced neurotoxicity while sensitizing leukemia cells to vincristine (2021) (7)
Pharmacogenomics of intracellular methotrexate polyglutamates in patients' leukemia cells in vivo. (2020) (7)
Asparaginase combined with discontinuous dexamethasone improves antileukemic efficacy without increasing osteonecrosis in preclinical models (2019) (7)
L-carnitine does not ameliorate asparaginase-associated hepatotoxicity in a C57BL6 mouse model (2019) (7)
MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia : a Children ’ s Oncology Group study (2014) (7)
Excellent Outcomes with Reduced Frequency of Vincristine and Dexamethasone Pulses in Children with National Cancer Institute (NCI) Standard-Risk B Acute Lymphoblastic Leukemia (SR B-ALL): A Report from Children's Oncology Group (COG) Study AALL0932 (2019) (7)
Expression of SMARCB 1 modulates steroid sensitivity in human lymphoblastoid cells : identification of a promoter snp that alters PARP 1 binding and SMARCB 1 expression (2007) (7)
Genome-wide association study of susceptibility loci for TCF3-PBX1 acute lymphoblastic leukemia in children. (2020) (6)
Pediatric acute lymphoblastic leukemia . Pediatric Acute Lymphoblastic Leukemia (2018) (6)
Whole‐joint magnetic resonance imaging to assess osteonecrosis in pediatric patients with acute lymphoblastic lymphoma (2020) (6)
Comparison Of Mutational Profiles Of Diagnosis and Relapsed Pediatric B-Acute Lymphoblastic Leukemia: A Report From The COG ALL Target Project (2013) (6)
Considerations for pharmacogenomic testing in a health system (2019) (6)
Mephenytoin phenotyping: lack of haematologic effect and timing of urine collections. (1991) (6)
Pharmacogenetics: Call to Action (2011) (6)
Incidence of hip and knee osteonecrosis and their associations with bone mineral density in children with acute lymphoblastic leukaemia (2020) (6)
Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase (2021) (5)
Non-coding germline GATA3 variants alter chromatin topology and contribute to pathogenesis of acute lymphoblastic leukemia (2020) (5)
Intrapatient variation in aminoglycoside disposition in cystic fibrosis. (1987) (5)
The Genomic Landscape of Childhood Acute Lymphoblastic Leukemia (2019) (5)
Concordant Gene Expression in Leukemia Cells and Normal Leukocytes Is Associated with Germline cis-SNPs (2008) (5)
Risk prediction of anthracycline-related cardiomyopathy (AC) in childhood cancer survivors (CCS): A COG-ALTE03N1 and CCSS report. (2019) (5)
The Genomic Landscape of Childhood T-Lineage Acute Lymphoblastic Leukemia (2015) (5)
Fenofibrate reduces osteonecrosis without affecting antileukemic efficacy in dexamethasone-treated mice (2020) (5)
Are children with lesser-risk B-lineage acute lymphoblastic leukemia curable with antimetabolite therapy? (2008) (5)
Individual prediction of nonadherence to oral mercaptopurine in children with acute lymphoblastic leukemia: Results from COG AALL03N1 (2021) (5)
Saturable elimination and saturable protein binding account for flavone acetic acid pharmacokinetics (1993) (5)
Higher plasma asparaginase activity after intramuscular than intravenous Erwinia asparaginase (2020) (5)
Identification of CYP2D6 Haplotypes that interfere with commonly used assays for Copy Number Variation characterization. (2021) (4)
Effects of NT5C2 germline variants on 6-mecaptopurine metabolism in children with acute lymphoblastic leukemia (2020) (4)
Can the genotoxicity of chemotherapy be predicted? (2004) (4)
Klinefelter syndrome and 47,XYY syndrome in children with B cell acute lymphoblastic leukaemia (2017) (4)
Lack of Somatic Sequence Mutations In Protein Tyrosine Kinase Genes Other Than the JAK Kinase Family In High Risk B-Precursor Childhood Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG) High-Risk (HR) ALL TARGET Project (2010) (4)
Comprehensive characterization of pharmacogenetic variants in TPMT and NUDT15 in children with acute lymphoblastic leukemia (2021) (4)
No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy (2019) (4)
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for thiopurine methyltransferase (TPMT) genotype and thiopurine dosing (2011) (4)
Challenges in clinical implementation of CYP2D6 genotyping: choice of variants to test affects phenotype determination (2019) (4)
Amino acid stress response genes promote L-asparaginase resistance in pediatric acute lymphoblastic leukemia (2021) (4)
High Intra-Individual Variability In Systemic Exposure To 6 Mercaptopurine (6MP) In Children With Acute Lymphoblastic Leukemia (ALL) Contributes To ALL Relapse: Results From a Children’s Oncology Group (COG) Study (AALL03N1) (2013) (4)
Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype (2022) (4)
Genetic and Response-Based Risk Classification Identifies a Subgroup of NCI High Risk Childhood B-Lymphoblastic Leukemia (HR B-ALL) with Outstanding Outcomes: A Report from the Children's Oncology Group (COG) (2015) (4)
6-Mercaptopurine (6MP) Intake during Maintenance for Childhood Acute Lymphoblastic Leukemia (ALL) - a Comparison of Self-Report and Electronic Monitoring: A Report from the Children's Oncology Group (COG) Study AALL03N1 (2015) (4)
Massive parallel variant characterization identifies NUDT15 alleles associated with thiopurine toxicity (2019) (3)
Outcomes with reduced intensity therapy in a low-risk subset of children with National Cancer Institute (NCI) standard-risk (SR) B-lymphoblastic leukemia (B-ALL): A report from Children’s Oncology Group (COG) AALL0932. (2020) (3)
Cumulative incidence of secondary neoplasms as the first event after treatment of childhood acute lymphoblastic leukemia increases over 30 years (2007) (3)
Effects of NT5C2 Germline Variants on 6‐Mecaptopurine Metabolism in Children With Acute Lymphoblastic Leukemia (2020) (3)
Genome-Wide Profiling of High-Risk Pediatric Acute Lymphoblastic Leukemia (ALL): The ALL Pilot Project for the Therapeutically Applicable Research To Generate Effective Treatments (TARGET) Initiative. (2007) (3)
Class II Human Leukocyte Antigen Variants Associate With Risk of Pegaspargase Hypersensitivity (2021) (3)
Germline Genetic Variation in IKZF1 and Predisposition to Childhood Acute Lymphoblastic Leukemia (2015) (3)
Advancing Pharmacogenomics from Single-Gene to Preemptive Testing. (2022) (3)
Genomic Medicine Year in Review: 2020. (2020) (3)
Molybdenum Cofactor Catabolism Unravels the Physiological Role of the Drug Metabolizing Enzyme Thiopurine S‐Methyltransferase (2022) (3)
Risk-Adapted Treatment for Acute Lymphoblastic Leukemia: Findings from St. Jude Children’s Research Hospital (1997) (3)
The impact of the UGT1A1*60 allele on bilirubin serum concentrations. (2017) (3)
Effects of zoledronic acid on osteonecrosis and acute lymphoblastic leukemia treatment efficacy in preclinical models (2021) (3)
Nonadherence to Oral 6-Mercaptopurine (6MP) in a Multi-Ethnic Cohort of Children with Acute Lymphoblastic Leukemia (ALL) and Its Impact On Relapse – a Children's Oncology Group (COG) Study (AALL03N1) (2012) (3)
Pharmacogenomics of adverse effects of anti-leukemic agents in children. (2012) (3)
CYP 2 B 6 , CYP 3 A 4 , AND CYP 2 C 19 ARE RESPONSIBLE FOR THE IN VITRO N-DEMETHYLATION OF MEPERIDINE IN HUMAN LIVER MICROSOMES (2004) (3)
Pharmacotypes across the genomic landscape of pediatric acute lymphoblastic leukemia and impact on treatment response (2022) (3)
A randomized trial of a mercaptopurine (6MP) adherence-enhancing intervention in children with acute lymphoblastic leukemia (ALL): A COG ACCL1033 study. (2019) (3)
Genome-Wide Association Study Identifies PNPLA3 I148M Variant Associated with Elevated Transaminase Levels after Induction Therapy in Pediatric ALL Patients (2015) (2)
Genetics of osteonecrosis in pediatric acute lymphoblastic leukemia and general populations. (2020) (2)
Non-Adherence to Oral 6-Mercaptopurine (6MP) Explains Ethnic Differences In Disease-Free Survival In Children with Acute Lymphoblastic Leukemia (ALL) – a Children's Oncology Group (COG) Study (AALL03N1) (2010) (2)
Syndrome of Inappropriate Secretion of Anti-Diuretic Hormone in Children with Acute Lymphoblastic Leukemia. (2006) (2)
Recombinant urate oxidase corrects hyperuricemia in patients treated for leukemia or lymphoma (1998) (2)
PDE4B Modulates Glucocorticoid Sensitivity in Childhood Acute Lymphoblastic Leukemia (2012) (2)
Incorporating G6PD genotyping to identify patients with G6PD deficiency (2021) (2)
ARID5B Regulates Leukemia Sensitivity to Antimetabolites in Children with Acute Lymphoblastic Leukemia Via Effects on Cell Cycle Progression (2014) (2)
Molecular mechanisms of ARID5B-mediated genetic susceptibility to acute lymphoblastic leukemia. (2022) (2)
The Clinical Pharmacogenetics Implementation Consortium (CPIC) Term Standardization for Clinical Pharmacogenetic Test Results: Alleles and Phenotypes (2016) (2)
Epigenomic profiling of glucocorticoid responses identifies cis-regulatory disruptions impacting steroid resistance in childhood acute lymphoblastic leukemia (2022) (2)
Dosing-related Saturation of Toxicity and Accelerated Drug Clearance with Pegaspargase Treatment. (2020) (2)
Genomic medicine year in review: 2021. (2021) (2)
The pharmacokinetics and pharmacodynamics of docetaxel (DCTX) in Caucasian and African American patients with solid tumors. (2004) (2)
Individualized versus fixed dosing of L-asparaginase during intensification therapy in children treated on Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocol 00–001 (2007) (2)
Glutamate Receptor Polymorphisms Contribute to Glucocorticoid-Associated Osteonecrosis (2014) (2)
Childhood Leukemias: Pharmacokinetic, pharmacodynamic, and pharmacogenetic considerations (2006) (2)
Continue to study childhood ALL. (2008) (2)
Impact of 6 Mercaptopurine (6MP) Pill-Taking Habits on Adherence, Thioguanine Nucleotide (TGN) Levels and Relapse Risk in Children with Acute Lymphoblastic Leukemia (ALL): Results from a Children’s Oncology Group (COG) Study (AALL03N1) (2014) (2)
Pharmacogenetics of Minimal Residual Disease Response in Children with Acute Lymphoblastic Leukemia (ALL). (2004) (2)
Reply to I.J. Cohen. (2017) (2)
Individual prediction of non-adherence to oral mercaptopurine (6MP) in children with acute lymphoblastic leukemia (ALL): Results from COG AALL03N1 study. (2020) (2)
Use of Genomic Technologies to Identify Novel Genetic Abnormalities and Therapeutic Targets In Acute Lymphoblastic Leukemia. (2008) (2)
Factors associated with nonadherence to oral 6-mercaptopurine (6MP) in children with acute lymphoblastic leukemia (ALL): A report from Children’s Oncology Group (COG) study AALL03N1. (2014) (2)
Response to: Unveiling the guidance heterogeneity for genome-informed drug treatment interventions among regulatory bodies and research consortia. (2020) (2)
Consortium ( CPIC ) guideline for thiopurine dosing based on TPMT and NUDT 15 genotypes : 2018 update (2018) (1)
Antileukemic Efficacy of Continuous Vs Discontinuous Dexamethasone in Murine Xenografts of Acute Lymphoblastic Leukemia (2014) (1)
Gestational trophoblastic neoplasm and women living with HIV and/or AIDS (2015) (1)
Abstract 222: Genome-wide association study of acute lymphoblastic leukemia in children with Down syndrome (2018) (1)
A semiparametric Bayesian model for repeatedly repeated binary outcomes (2008) (1)
we get there? Pediatric acute lymphoblastic leukemia: where are we going and how do (2012) (1)
Series ACUTE LYMPHOBLASTIC LEUKEMIA Inherited genetic variation in childhood acute lymphoblastic leukemia (2015) (1)
Characterization of Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia (2018) (1)
Up-Regulation of Genes Involved in Folate Metabolism Characterize Late but Not Early Relapse in Childhood Acute Lymphoblastic Leukemia. (2009) (1)
Genetically Defined Racial Differences Underlie Risk of Relapse in Childhood Acute Lymphoblastic Leukemia (2008) (1)
Implementation of Pharmacogenomics: Evidence Needs (2015) (1)
A Genome-Wide Analysis of Variants Influencing Methotrexate Clearance Replicates SLCO1B1. (2012) (1)
Genomic Landscape of Relapsed Acute Lymphoblastic Leukemia (2015) (1)
Comprehensive Functional Characterization of Germline ETV6 Variants Associated with Inherited Predisposition to Acute Lymphoblastic Leukemia in Children (2016) (1)
Risk Factors For Acute Pancreatitis In Patients With Acute Lymphoblastic Leukemia (2013) (1)
Comprehensive analysis of dose intensity of acute lymphoblastic leukemia chemotherapy (2021) (1)
The Changing Burden of Late Health Outcomes in Adult Survivors of Childhood Acute Lymphoblastic Leukemia: A Report from the St. Jude Lifetime Cohort Study (2019) (1)
A Genome-Wide Approach Identifies Variations in the Aspartate Metabolism Pathway That Are Associated with Asparaginase Sensitivity (2008) (1)
Hospital results of Total Therapy Study XIIIB at St Jude Children's Research Improved outcome for children with acute lymphoblastic leukemia: (2013) (1)
Dasatinib does not exacerbate dexamethasone‐induced osteonecrosis in murine models of acute lymphoblastic leukemia therapy (2021) (1)
Late Outcomes of Adult Survivors of Childhood Acute Lymphoblastic Leukemia (ALL) Diagnosed Between 1963-2002: A Report from the St. Jude Lifetime (SJLIFE) Cohort Study (2014) (1)
Germline RUNX1 Variation and Predisposition to T-Cell Acute Lymphoblastic Leukemia in Children (2019) (1)
Osteonecrosis is unrelated to hip anatomy in children with acute lymphoblastic leukemia (2017) (1)
Reduced Folate Carrier Expression in Acute Lymphoblastic Leukemia: A Mechanism for Ploidy but not Lineage Differences in Methotrexate Accumulation (1999) (1)
Genetic Polymorphisms and the Toxicity of Antileukemic Agents in Children with Acute Lymphoblastic Leukemia. (2004) (1)
Characterization of Causal Variants at the GATA3 Loci Associated with Susceptibility to Ph-like Acute Lymphoblastic Leukemia (2017) (1)
leukemia determinants of osteonecrosis in children with acute lymphoblastic Pharmacokinetic, pharmacodynamic, and pharmacogenetic (2011) (1)
An injectable excipient prevents anti‐polyethylene glycol antibody‐mediated hypersensitivity (2021) (1)
ARID5B Genetic Polymorphisms Contribute to Racial Disparities In Childhood Acute Lymphoblastic Leukemia: A Children's Oncology Group Study (2010) (1)
Prevalence and Predictors of Non-Adherence to 6-Mercaptopurine (6MP) in Children with Acute Lymphoblastic Leukemia (ALL) - a Children’s Oncology Group Study. (2008) (1)
Genome-Wide Association Study Identifies a Novel Susceptibility Locus At 10p12.31-12.2 for Childhood Acute Lymphoblastic Leukemia in Ethinically Diverse Populations (2012) (1)
diagnosis to relapse in childhood acute lymphoblastic leukemia Genome-wide copy number profiling reveals molecular evolution from (2013) (1)
Children with t(12;21)/TEL-AML1-Positive Acute Lymphoblastic Leukemia Exhibit a Distinct Germline Genomic Signature. (2007) (1)
Secondary Myeloid Malignancy after Treatment of Acute Lymphoblastic Leukemia (ALL) (2009) (1)
Pegaspargase Allergic Reactions Are Related to Anti-Pegaspargase Antibodies and to Intensity of Intrathecal Therapy (2018) (1)
Genomic Variants Associated with Childhood Acute Lymphoblastic Leukemia (2010) (1)
High Resolution Genomic Profiling Using Single Nucleotide Polymorphism Microarrays Identifies Multiple Novel Genomic Lesions in Pediatric Acute Lymphoblastic Leukemia. (2006) (1)
Pharmacogenetic and Pharmacogenomic Considerations in the Biology and Treatment of Childhood Leukemia (2011) (1)
Venous Thrombosis in Children Treated for Acute Lymphoblastic Leukemia on St. Jude Total Therapy Studies: ALL‐054 (2018) (1)
Genes Regulating B-Cell Development and Differentiation Are Mutated in 40% of Pediatric Acute Lymphoblastic Leukemia. (2006) (1)
HLA-DRB1*07:01 Is Associated With Asparaginase Allergies In Children With Acute Lymphoblastic Leukemia (2013) (1)
SLCO1B1 Variation and Methotrexate Disposition in Children with Acute Lymphoblastic Leukemia: The Importance of Rare Variants in Pharmacogenetics (2011) (1)
Clofarabine-Based Chemotherapy for KMT2Ar Infantile Acute Lymphoblastic Leukemia (2021) (1)
DPYD Testing: Time to Put Patient Safety First. (2023) (1)
Total ifosfamide excretion in the urine of pediatric patients and enantiomeric composition (1991) (0)
ACUTE LYMPHOBLASTIC LEUKEMIA Inherited genetic variation in childhood acute lymphoblastic leukemia (2015) (0)
Excellent Outcome for ETV6/RUNX1-Positive Childhood Acute Lymphoblastic Leukemia (ALL) with Contemporary Therapy (2010) (0)
Hepatic injury after treatment for childhood cancer: A report from the St. Jude Lifetime Cohort study. (2017) (0)
Systemic Exposure to Dexamethasone and Asparaginase Affects Risk of Relapse in Children with Acute Lymphoblastic Leukemia (2011) (0)
Association of Inherited Genetic Factors With Drug-Induced Hepatic Damage Among Children With Acute Lymphoblastic Leukemia (2022) (0)
Group acute lymphoblastic leukemia: a report from the Children's Oncology A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with (2013) (0)
Homocysteine, P harmacogenetics , a nd N eurotoxicity i n Children W ith L eukemia (2003) (0)
Inosine-Triphosphate-Pyrophosphatase Genotype Is a Determinant of Severe Fever with Neutropenia Following Treatment of Acute Lymphoblastic Leukemia with Combination Chemotherapy That Includes Mercaptopurine Adjusted for Thiopurine-S-Methyltransferase Genotype. (2007) (0)
Genetic Variations in GRIA1 On Chromosome 5q33 Related to Asparaginase Hypersensitivity in Childhood Acute Lymphoblastic Leukemia (ALL). (2009) (0)
A Whole Genome Analysis Identifies SLCO1B1 as a Determinant of Methotrexate Pharmacokinetics and Adverse Effects (2008) (0)
The Effect of Asparaginase on Serum Triglycerides during Therapy for Acute Lymphoblastic Leukemia (2018) (0)
Evolution of Gene Expression Signatures in Relapsed Childhood Acute Lymphoblastic Leukemia Differs Based on Timing of Relapse. (2008) (0)
CYP1A2 4‐hydroxylates propranolol (1999) (0)
Acute lymphoblastic leukemia. (2002) (0)
OP-JNCI200138 933..937 (2021) (0)
Concordance between glucose-6-phosphate dehydrogenase (G6PD) genotype and phenotype and rasburicase use in patients with hematologic malignancies (2018) (0)
Inherited GATA3 genetic Variants Are Associated With Childhood BCR-ABL1-Like Acute Lymphoblastic Leukemia and Increased Risk Of Relapse (2013) (0)
ALL-144: Oncogenic Deregulation of BCL11B in Lineage Ambiguous Leukemia (2021) (0)
Outstanding outcomes with two low intensity regimens in children with low-risk B-ALL: a report from COG AALL0932. (2023) (0)
Functional investigation of inherited noncoding genetic variation impacting the pharmacogenomics of childhood acute lymphoblastic leukemia treatment (2023) (0)
Body Mass Index Is Not Associated with Early Treatment Response or Clinical Outcome in Children with Acute Lymphoblastic Leukemia (2015) (0)
Erratum to: Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments (2013) (0)
leukemia reveals therapeutic strategies Integrated genomic analysis of relapsed childhood acute lymphoblastic (2012) (0)
Leukemia Central Nervous System Relapse in Children With Acute Lymphoblastic Early Intensification of Intrathecal Chemotherapy Virtually Eliminates (2013) (0)
Longitudinal evaluation of alanine aminotransferase after treatment for childhood cancer. A report from the St. Jude Lifetime Cohort Study. (2020) (0)
Genome-Wide Profiling Reveals Recurring Molecular Defects in Relapsed Childhood Acute Lymphoblastic Leukemia (ALL): A Children’s Oncology Group Study. (2007) (0)
Epigenomic mapping in B-cell acute lymphoblastic leukemia identifies transcriptional regulators and noncoding variants promoting distinct chromatin architectures (2023) (0)
malignancy after etoposide treatment Granulocyte colony-stimulating factor and the risk of secondary myeloid (2013) (0)
Chromatin Accessibility Landscapes of B-Cell Acute Lymphoblastic Leukemia Identify Extensive Epigenomic Reprogramming and Heterogeneity Among Subtypes (2022) (0)
A novel association between GSTM1 null variant and anthracycline-induced cardiac dysfunction (ACD) in childhood cancer survivors (CCS): A COG ALTE03N1 report. (2019) (0)
HLA Haplotype DRB1*07:01-DQA1*02:01-DQB1*02:02 Predicts Pegaspargase Hypersensitivity (2020) (0)
Host Thiopurine Methyltransferase Status Affects Mercaptopurine Antileukemic Effectiveness (2012) (0)
Identification of Gene Expression Profiles in Acute Lymphoblastic Leukemia Cells That Discriminate Intracellular Thioguanine Nucleotide Accumulation in ALL Cells after In Vivo Treatment with Mercaptopurine. (2004) (0)
Germline exome variation in children with acute lymphoblastic leukemia (ALL): Preliminary Findings (2015) (0)
A research agenda to support the development and implementation of genomics-based clinical informatics tools and resources (2022) (0)
Abrogation of etoposides illicit V J-recombination without attenuating efficacy using prolonged exposure (1996) (0)
Clinician adherence to pharmacogenomics prescribing recommendations in clinical decision support alerts (2022) (0)
Predicting risk for non-adherence to oral 6-mercaptopurine (6MP) in children with acute lymphoblastic leukemia (ALL) results from the Children's Oncology Group AALL03N1 study. (2016) (0)
Asparaginase May Affect Mercaptopurine Tolerability in the Context of Multi-Agent Therapy for Acute Lymphoblastic Leukemia (2016) (0)
lymphoblastic leukemia asparaginase and asparaginase antibodies in pediatric acute Erwinia A prospective study on drug monitoring of PEGasparaginase and (2014) (0)
Reply to C.D. Atkins (2012) (0)
Deletion of IKZF1 (Ikaros) Predicts Poor Outcome and Impaired Maturation in B-Progenitor Acute Lymphoblastic Leukemia (2008) (0)
MLL methylation is not likely a common mechanism for therapy-related AML (2005) (0)
A Murine Model of Asparaginase Allergy (2014) (0)
Semimechanistic PK/PD model for methotrexate including homocysteine levels as biomarker for neurotoxicity (2011) (0)
Mapping the Glucocorticoid Gene Regulatory Network and Alterations That Contribute to Steroid Resistance in Childhood Acute Lymphoblastic Leukemia (2021) (0)
Considerations for pharmacogenomic testing in a health system (2019) (0)
Genome-wide copy number proﬁling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia (2008) (0)
Cumulative incidence of second neoplasms over 30 years after treatment of childhood acute lymphoblastic leukemia (ALL) (2005) (0)
METHOTREXATE, IN VIVO OF MERCAPTOPURINE ALONE OR IN COMBINATION WITH DE NOVO PURINE SYNTHESIS INHIBITION AND ANTILEUKEMIC EFFECTS (2013) (0)
Genome-wide association study identiﬁes germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia (2012) (0)
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia (2019) (0)
Abstract PR-2: Characterization of germline genetic variants underlying racial disparities of childhood leukemia outcome (2009) (0)
Choosing a sunscreen. (1983) (0)
Recombinant U rate O xidase f or t he P rophylaxis o r Treatment o f H yperuricemia i n P atients W ith L eukemia or L ymphoma (2001) (0)
Correction: Prevention of Hemorrhagic Cystitis after Cyclophosphamide (1990) (0)
Sex D ifferences i n P rognosis f or C hildren W ith A cute Lymphoblastic L eukemia (1999) (0)
Using hapmap tools to predict oncology-related phenotypes: TPMT activity vs hapmap SNPs. (2006) (0)
lymphoblastic leukemia: a report from the Children's Oncology Group Key pathways are frequently mutated in high-risk childhood acute (2013) (0)
Pediatric Neoplastic Disorders (1992) (0)
Pharmacodynamics and Tolerability of Twice-Weekly Erwinia Asparaginase after E. coli Asparaginase Allergy in Children with ALL. (2006) (0)
YEAR IN REVIEW Genomic Medicine Year in Review: 2020 (2020) (0)
Abstract CT146: Prognostic and therapeutic significance of leukemia subtypes in the context of risk-directed therapy based on minimal residual disease levels in pediatric acute lymphoblastic leukemia (2021) (0)
Genetic and Epigenetic Cis-Regulatory Disruptions Impacting the Canonical Wnt Signaling Repressor TLE1 Gene Promote Glucocorticoid Resistance in Childhood Acute Lymphoblastic Leukemia (2022) (0)
Abstract 2118: Non-coding germline GATA3 variants alter chromatin topology and contribute to pathogenesis of acute lymphoblastic leukemia (2021) (0)
Incorporating genotyping to identify patients with G6PD deficiency (2021) (0)
Pharmacodynamics Methyltransferase on Mercaptopurine and Thioguanine Differential Effects of Targeted Disruption of Thiopurine (2007) (0)
Amino acid stress response genes promote L-asparaginase resistance in pediatric acute lymphoblastic leukemia (2022) (0)
POSTER SESSION II (2015) (0)
Hypersensitivity o r D evelopment o f A ntibodies t o Asparaginase D oes N ot I mpact T reatment O utcome o f Childhood A cute L ymphoblastic L eukemia (2000) (0)
Epigenetic Fine Mapping and Functional Dissection of Inherited Non-Coding Variation Impacting the Pharmacogenomics of Acute Lymphoblastic Leukemia Treatment (2022) (0)
Tolerability of 6-Mercaptopurine (6MP) in Patients with Thiopurine Methyltransferase (TPMT) Heterozygosity in the Context of Multi-Agent Therapy for Acute Lymphoblastic Leukemia (ALL) (2014) (0)
Genetic Polymorphisms in the Promoter Region of the beta-2 Adrenergic Receptor Are Associated with the Early Response of Acute Lymphoblastic Leukemia to Chemotherapy. (2004) (0)
Genome Scan for Therapy-Related Leukemia. (2005) (0)
Pharmacogenomics of childhood acute lymphoblastic leukemia (ALL). (2009) (0)
Folate Pathway Gene Expression Differs in Genetic Subtypes of Acute Lymphoblastic Leukemia and Influences Methotrexate Pharmacodynamics. (2004) (0)
Gene Expression Profiles Distinguish Children Who Develop Therapy-Related Myeloid Leukemia. (2004) (0)
Erratum: Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments (Cancer Chemother Pharmacol (2013) 72 (369-378) DOI 10.1007/s00280-013-2206-x) (2013) (0)
Integrated analysis of 179 validated somatic sequence mutations with genome-wide copy number alterations and gene expression profiles revealed a high frequency of recurrent somatic alterations in key signaling pathways including B cell development/differentiation (2011) (0)
High-Dose Methotrexate, Ifosfamide, Etoposide and Dexamethasone (MIED) Is an Active Salvage Regimen for Children with Recurrent or Refractory Malignant Lymphoma. (2007) (0)
An end to pharmacogenetic exceptionalism (2019) (0)
Zoledronic Acid Reduces Osteonecrosis and Anti-Leukemic Efficacy in Murine Models of Acute Lymphoblastic Leukemia Therapy (2018) (0)
Challenges in clinical implementation of CYP2D6 genotyping: choice of variants to test affects phenotype determination (2019) (0)
Long-Term Functional Outcomes Among Childhood Cancer Survivors with Osteonecrosis (2017) (0)
A SERPINE1 ( PAI-1 ) Single Nucleotide Polymorphism Predicts Osteonecrosis in Children Treated for Acute Lymphoblastic Leukemia: Results of the Children’s Oncology Group (COG) Study AALL03B2. (2006) (0)
Targeted Drug Therapy in Childhood Acute Lymphoblastic Leukemia (1996) (0)
Genetic Variation in NFATC2 Is Associated with a Higher Risk of Asparaginase Allergy (2014) (0)
Pharmacogenetics Implementation: Current Programs in Five US Medical (2015) (0)
Pharmacodynamics in Childhood Acute Lymphoblastic Leukemia (2001) (0)
Genomic Medicine Year in Review: 2022. (2022) (0)
Etoposide in Acute Leukemias: Therapeutic and Pharmacokinetic Considerations (2002) (0)
Pharmacokinetics a nd P harmacodynamics o f O ral E toposide i n Children W ith R elapsed o r R efractory A cute Lymphoblastic L eukemia (2003) (0)
Genomics into Rational Therapeutics Pharmacogenomics : Translating Functional (2009) (0)
Etoposide Sensitivity Does Not Predict MLL Rearrangements or Risk of Therapy-Related Acute Myeloid Leukemia. (2007) (0)
Etoposide in Acute Leukemias (2003) (0)
Abstract 998: Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukemia (B-ALL): A report from the children's oncology group (COG) - Target - St. Jude Pediatric Cancer Genome Project (2014) (0)
Global Gene Expression in Leukemic Blasts as a Function of Germline Genetic Variation. (2004) (0)
Identification of New Risk Loci and Regulatory Mechanisms Influencing Genetic Susceptibility to Acute Lymphoblastic Leukaemia (2019) (0)
Multiplex assessment of protein variant abundance by massively parallel sequencing (2018) (0)
Abstract CT409: Dexamethasone (dex) and asparaginase increase triglycerides during acute lymphoblastic leukemia (ALL) therapy in children (2014) (0)
Measuring mercaptopurine (6MP) adherence using red cell 6MP metabolite levels in children with acute lymphoblastic leukemia (ALL): A COG AALL03N1 study. (2017) (0)

This paper list is powered by the following services:

Other Resources About Mary V. Relling

en.wikipedia.org

What Schools Are Affiliated With Mary V. Relling?

Mary V. Relling is affiliated with the following schools: